Cite

HARVARD Citation

    Gayko, U. et al. (2015). Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies. Annals of the New York Academy of Sciences. 1358 (1), pp. 82-94. [Online]. 
  
Back to record